Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
Valerie C. Montgomery Rice M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition of 40 shares of common stock on 09/23/2025. The shares were recorded as dividend equivalents on vested deferred stock units and carried a $0 price; the filing shows 6,627 shares owned after the transaction. The dividend equivalents are immediately vested and subject to the same terms as the underlying deferred stock units. The Form 4 was signed by attorney‑in‑fact Faraz A. Choudhry on 09/25/2025.
Erin L. McSweeney, Executive Vice President and Chief People Officer of UnitedHealth Group (UNH), reported a non‑cash acquisition on 09/23/2025 consisting of 36.837 shares of common stock recognized as dividend equivalents on outstanding restricted stock units. The reported price is $0 because these shares represent dividend equivalents rather than a market purchase. Following this issuance, McSweeney beneficially owns 11,154.072 shares. The filing notes the dividend equivalents follow the same vesting terms as the underlying restricted stock units and are forfeitable if those units do not vest.
Christopher R. Zaetta, EVP & Chief Legal Officer of UnitedHealth Group (UNH), received 42.53 dividend-equivalent shares on 09/23/2025 that were paid on outstanding restricted stock units and are subject to the same vesting and forfeiture terms as the underlying RSUs. The transaction was reported on a Form 4 executed by an attorney-in-fact on 09/25/2025. The reported shares were issued at a $0 price as dividend equivalents and increase the reporting person’s beneficial ownership to 10,283.276 shares following the transaction.
UnitedHealth Group (UNH) Form 4: This filing reports a non-derivative acquisition by Thomas E. Roos, Chief Accounting Officer, via an authorized filing on behalf of the reporting person. On 09/23/2025 the report shows an acquisition of 22.357 units recorded as dividend equivalents on outstanding restricted stock units, with a reported price of $0 because these are dividend-equivalent payments tied to RSUs and subject to the same vesting and forfeiture terms as the underlying awards. Following the transaction, the reporting person beneficially owned 29,593.519 shares, which includes shares acquired through UnitedHealth’s Employee Stock Purchase Plan. The filing was signed by an attorney-in-fact on 09/25/2025.
Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), filed a Form 4 reporting changes in his beneficial ownership. The filing shows a transaction dated 09/11/2025 reporting 27 shares of Common Stock with transaction code S at a price of $356.05. The Form reports that following the reported transaction the reporting person had 1,248 shares of Common Stock beneficially owned indirectly (by trust). The form also explains that on 08/01/2025 the reporting person acquired indirect beneficial ownership of 27 UNH shares by inheritance, an acquisition the filer states was exempt from reporting under Rules 16a-3 and 16b-5.
UnitedHealth Group (UNH) filer submitted a Form 144 reporting a proposed sale of company common stock. The notice shows 27 shares intended for sale on the NYSE through J.P. Morgan Securities LLC with an aggregate market value of $9,363.06 and an approximate sale date of 09/11/2025. The securities were acquired by transfer on 08/01/2025 from the "Barbara L S Schadt Terminating Trust UAD 12-16-2015" and payment/consideration is listed as N/A. The form indicates no securities sold in the prior three months and contains standard signature and representation language. Some filer identifiers and contact details are not provided in the content.
UnitedHealth Group reaffirmed its adjusted 2025 earnings-per-share outlook and said that the August 2025 acquisition of Amedisys is incorporated into that outlook, noting the acquisition is expected to be dilutive to adjusted EPS because of financing costs and integration investments. The company also discussed preliminary CMS Medicare Advantage star ratings for Star Year 2026/Payment Year 2027 and estimated that about 78% of its membership will be in plans rated 4 stars or higher, which the company says is consistent with expectations and historical performance. The report reiterates customary forward-looking statement cautions and lists factors that could cause actual results to differ materially.
UnitedHealth Group, Inc. filed a Current Report on Form 8-K noting that the document contains forward-looking statements about its financial prospects, operations and risks. The filing lists common examples of forward-looking language and explains that actual results may differ materially due to factors such as medical cost trends, regulatory or legal actions, cybersecurity incidents, changes in government programs, quality scores affecting revenue, contract or market risks, and other operational or financial risks. The company cautions investors not to place undue reliance on these statements and says it will not update them except as required by law.
Wayne S. DeVeydt, Chief Financial Officer of UnitedHealth Group (UNH), reported equity awards on 09/02/2025. He was granted 10,525 restricted stock units and 42,551 non-qualified stock options tied to common stock. The RSUs and options were reported as acquired at $0 on the filing; the options carry an exercise price of $308.8. Both the RSUs and the options vest 25% annually on September 2 in 2026, 2027, 2028 and 2029. Following the transactions, DeVeydt beneficially owns 10,525 shares from the RSUs and the options represent the right to purchase 42,551 shares. The report is a routine Section 16 disclosure of insider compensation-related equity grants.
FAQ
What is the current stock price of Unitedhealth Gp (UNH)?
What is the market cap of Unitedhealth Gp (UNH)?
